Stockscreener 앱 받기
84.47
0.51%
-0.43
시간 외 거래:
84.50
0.03
+0.04%
전일 마감가:
$84.90
열려 있는:
$85.89
하루 거래량:
12.91M
Relative Volume:
1.09
시가총액:
$147.13B
수익:
$45.13B
순이익/손실:
$6.28B
주가수익비율:
23.53
EPS:
3.5895
순현금흐름:
$7.38B
1주 성능:
+0.18%
1개월 성능:
-16.83%
6개월 성능:
-35.32%
1년 성능:
-36.66%
1일 변동 폭
$84.13
$86.47
1주일 범위
$81.97
$86.47
52주 변동 폭
$81.97
$139.06
애보트 래버러토리스 Stock (ABT) Company Profile
명칭
Abbott Laboratories
전화
(224) 667-6100
주소
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
84.47 | 147.88B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
306.76 | 117.12B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
76.15 | 98.82B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
52.68 | 79.59B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
81.38 | 46.84B | 6.30B | 1.07B | 1.09B | 1.8406 |
애보트 래버러토리스 Stock (ABT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-22 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2025-10-10 | 개시 | The Benchmark Company | Buy |
| 2025-07-18 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-06-16 | 개시 | Leerink Partners | Market Perform |
| 2024-10-08 | 개시 | Oppenheimer | Outperform |
| 2024-09-19 | 개시 | Piper Sandler | Overweight |
| 2024-07-30 | 다운그레이드 | Edward Jones | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2023-07-21 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | 재확인 | Barclays | Overweight |
| 2023-04-20 | 재확인 | Bernstein | Outperform |
| 2023-04-20 | 재확인 | JP Morgan | Overweight |
| 2023-04-20 | 재확인 | Raymond James | Outperform |
| 2023-04-20 | 재확인 | UBS | Buy |
| 2023-04-20 | 재확인 | Wolfe Research | Underperform |
| 2023-03-29 | 개시 | UBS | Buy |
| 2022-10-26 | 개시 | Mizuho | Neutral |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-07-06 | 개시 | Wolfe Research | Underperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-01-27 | 재확인 | Credit Suisse | Outperform |
| 2022-01-27 | 재확인 | Morgan Stanley | Overweight |
| 2022-01-27 | 재확인 | Raymond James | Outperform |
| 2022-01-27 | 재확인 | UBS | Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-10-27 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | 개시 | Redburn | Neutral |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Neutral |
| 2021-01-28 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2020-09-11 | 개시 | Wolfe Research | Outperform |
| 2020-06-01 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-06-13 | 재확인 | BofA/Merrill | Buy |
| 2019-02-07 | 재확인 | BofA/Merrill | Buy |
| 2019-01-02 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2018-11-30 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-10-16 | 개시 | Barclays | Overweight |
| 2018-06-27 | 개시 | Bernstein | Outperform |
| 2018-01-30 | 재확인 | Citigroup | Neutral |
| 2018-01-25 | 재확인 | Stifel | Buy |
| 2018-01-25 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | 개시 | Evercore ISI | Outperform |
| 2018-01-02 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-01-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-19 | 재확인 | Stifel | Buy |
모두보기
애보트 래버러토리스 주식(ABT)의 최신 뉴스
Abbott Laboratories stock (US0028241000): diabetes segment drives attention after latest quarterly u - AD HOC NEWS
Abbott Laboratories Trade Ideas — LSX:850103 - TradingView
Assessing Abbott Laboratories (ABT) Valuation After Nutrition Setbacks Legal Uncertainty And Softer Analyst Sentiment - simplywall.st
ABT (NYSE: ABT) Form 144 shows 7,587 RSU shares and prior 29,211 sale - Stock Titan
Abbott Laboratories cuts outlook, says mild flu season hurt sales - MSN
Is Abbott’s Exact Sciences Deal And Nutrition Pivot Altering The Investment Case For Abbott (ABT)? - Yahoo Finance
Better medical device stock right now: Abbott Laboratories vs. Dexcom - MSN
Abbott Laboratories slammed on its post-Exact Sciences guidance - MSN
Is the options market predicting a spike in Abbott Laboratories stock? - MSN
Abbott Laboratories stock (US0028241000): Q1 beat, Exact Sciences deal and legal risks keep investor - AD HOC NEWS
Abbott class action alleges FreeStyle Libre 2 glucose monitor is defective - Class Action Lawsuits
How Abbott's Volume-Driven Nutrition Strategy Is Shaping Up - Yahoo Finance
Exact Sciences Deal and Legal Pressures Might Change The Case For Investing In Abbott (ABT) - simplywall.st
Global Cervical Cancer Diagnostics Market to Exhibit Growth at a CAGR of ~5% by 2034 | DelveInsight - GlobeNewswire Inc.
ABT Stock Quote Price and Forecast - CNN
Exact Sciences Corp. stock (US30063P1057): Acquired by Abbott for $20.6B - AD HOC NEWS
Jim Cramer Compares the Current Selloff in Abbott Labs to the 1999 Market Environment - Insider Monkey
Abbott Laboratories stock (US0028241000): shares rebound after earnings and guidance update - AD HOC NEWS
Insider trades: Okta and Abbott see buys, Micron insiders sell - MSN
What to know about Kyle Diamantas, the new acting FDA commissioner - The Guardian
How The Investment Narrative For Abbott Laboratories (ABT) Is Shifting With Recent Analyst Resets - Yahoo Finance
Nvision secures $55 million, with backing from Abbott - BioWorld News
Abbott Eterna Lawsuit Alleges Spinal Cord Stimulator Malfunction Resulted in Worsening Pain - AboutLawsuits.com
Abbott Laboratories Deadline Alert - TMX Newsfile
Abbott Laboratories stock (US0028241000): Q4 earnings call set for Jan. 22 - AD HOC NEWS
Abbott Stock at 52-Week Low After Q1 Earnings: Book Profits or Hold? - Yahoo Finance
Abbott Securities Lawsuit Deepens Infant Formula Risks For Shareholders - simplywall.st
Abbott India Limited Issues Postal Ballot Notice for Appointment of Mr. James Wenner and Mr. Neeraj Jain to Its Board - scanx.trade
Abbott Laboratories stock outperforms competitors on strong trading day - MarketWatch
Q1 2026 earnings beat sends Abbott stock higher by 3.04% - Traders Union
Abbott’s dividend yield near decade peak as investors weigh litigation costs By Investing.com - Investing.com Nigeria
Abbott’s dividend yield near decade peak, signaling rare buying opportunity - Investing.com
Abbott Laboratories (NYSE:ABT) Sets New 52-Week LowHere's Why - MarketBeat
Abbott Laboratories stock (US0028241000): Q1 earnings beat with $11.16B revenue - AD HOC NEWS
ABT Stock Price, Quote & Chart | ABBOTT LABORATORIES (NYSE:ABT) - ChartMill
Could Cash Machine Abbott Laboratories Stock Be Your Next Buy? - Trefis
Operating margin % of Abbott Laboratories Shs UnSponsored Canadian Depository Receipt Hedged – TSX:ABT - TradingView
Jim Cramer says today’s market is punishing stocks harder than 1999 - CNBC
Abbott Laboratories Shs UnSponsored Canadian Depository Receipt Hedged Statistics – TSX:ABT - TradingView
Abbott Laboratories stock underperforms Monday when compared to competitors - MarketWatch
Why is Abbott Laboratories stock down today? - Traders Union
Abbott Stock Down 38% in 2026: Does the $23 Billion Exact Sciences Acquisition Change the Math? - TIKR.com
Abbott Laboratories trades at decade low with growth and dividend streak, poised for EPS boost by 2028-29. - Pluang
Abbott: Three Supercycles, Mispriced At A 10-Year Low - Seeking Alpha
Abbott Laboratories stock (US0028241000): Q1 earnings beat estimates with $11.16B revenue - AD HOC NEWS
Abbott Laboratories stock (US0028241000): Kepler Cheuvreux Suisse buys new stake - AD HOC NEWS
Wearable Skin Patch Market Size Propelled by 12.8% CAGR | - openPR.com
Implantable Medical Devices Market Is Going to Boom | Medtronic, Abbott Laboratories - openPR.com
Helicobacter Pylori Testing Market Is Going to Boom | Abbott Laboratories, Roche Diagnostics, Siemens Healthineers - openPR.com
Lateral Flow Assay Component Market Is Going to Boom | Abbott Laboratories, BD - openPR.com
Abbott Laboratories (ABT) Stock Analysis: Strong Buy Ratings Signal Potential 40.7% Upside - DirectorsTalk Interviews
애보트 래버러토리스 (ABT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
애보트 래버러토리스 주식 (ABT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| STARKS DANIEL J | Director |
Apr 27 '26 |
Buy |
92.65 |
10,000 |
926,537 |
6,751,103 |
0.41%
1.07%
자본화:
|
볼륨(24시간):